Results
|
|
2101.
|
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. [electronic resource] by
- De Witte, T
- Suciu, S
- Selleslag, D
- Labar, B
- Roozendaal, K
- Zittoun, R
- Ribeiro, M
- Kurstjens, R
- Hayat, M
- Dardenne, M
- Solbu, G
- Muus, P
Producer: 19961216
In:
Annals of hematology vol. 72
Availability: No items available.
|
|
|
2102.
|
|
|
|
2103.
|
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. [electronic resource] by
- Gerrits, C J
- Creemers, G J
- Schellens, J H
- Wissel, P
- Planting, A S
- Kunka, R
- Selinger, K
- de Boer-Dennert, M
- Marijnen, Y
- Harteveld, M
- Verweij, J
Producer: 19960604
In:
British journal of cancer vol. 73
Availability: No items available.
|
|
|
2104.
|
|
|
|
2105.
|
|
|
|
2106.
|
|
|
|
2107.
|
|
|
|
2108.
|
|
|
|
2109.
|
|
|
|
2110.
|
|
|
|
2111.
|
|
|
|
2112.
|
|
|
|
2113.
|
|
|
|
2114.
|
|
|
|
2115.
|
|
|
|
2116.
|
|
|
|
2117.
|
|
|
|
2118.
|
|
|
|
2119.
|
|
|
|
2120.
|
|